Fabrazyme

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
0520022016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Purpose:Fabry disease is a rare, X-linked, inherited lysosomal storage disorder that can be treated with the enzymes agalsidase… (More)
Is this relevant?
2011
2011
The recent shortages of enzyme replacement therapy for Fabry disease have highlighted areas of vulnerability for patients who… (More)
Is this relevant?
2010
2010
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in alpha-galactosidase A (alpha-Gal A) activity… (More)
Is this relevant?
2009
2009
Patients that are exposed to biotechnology-derived therapeutics often develop antibodies to the therapeutic, the magnitude of… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2009
2009
Fabry disease results from a genetic deficiency of alpha-galactosidase A (alpha GAL) and the impaired catabolism of… (More)
Is this relevant?
2008
2008
OBJECTIVE To evaluate the safety and explore the efficacy of enzyme replacement therapy with agalsidase beta (recombinant human… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human alpha -galactosidase A… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2004
2004
Fabry's disease is an X-linked lysosomal storage disease caused by a deficiency of alpha-galactosidase that results in an… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Enzyme replacement therapy (ERT) has been shown to enhance microvascular endothelial globotriaosylceramide clearance… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?